See our coverage on
I AM ALS comments regarding FDA refusal to file
Yesterday, the Food and Drug Administration (FDA) issued a refusal to file letter regarding NurOwn.
I AM ALS supports PVA comments to FAA regarding air accessibility and safety for people with disabilities
NINDS releases draft of ALS Strategic Plan
I AM ALS is pleased that the National Institute of Neurological Disorders and Stroke (NINDS) released their ALS Strategic Plan.
NINDS has awarded the first Expanded Access Grant under ACT for ALS
Today, September 30, 2022, the National Institute of Neurological Disorders and Stroke (NINDS) awarded the first of what we hope to be many Expanded Access Program (EAP) grants to help people with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for clinical trials.
We will find cures for ALS. The only question is when. That answer depends on you.
Stay informed on I AM ALS’ progress and what you can do to help us make hope real.
I AM ALS statement regarding 7 – 2 vote in favor of AMX0035 approval
On September 7, 2022, the Peripheral and Central Nervous System Drugs Advisory Committee (AdCom) met for the second time to discuss the New Drug Application (NDA) for AMX0035. After hearing from clinicians, scientists, field experts, and people living with ALS, the committee voted 7 - 2 in favor of approval!
Guide to Submitting Written Testimony to the FDA about AMX0035
On September 7, 2022, the FDA will host their second public advisory committee meeting (AdCom) about AMX0035.
Response to NINDS ALS Strategic Plan Request for Information
On Feb 10, 2022 I AM ALS submitted a response to the National Insititute of Neurological Disorders and Stroke (NINDS) ALS Strategic Plan Request for Information. NINDS is a part of the National Institute of Health (NIH), which is the largest public funder of ALS research.
A Look Back at 2021
We are a community-centric platform and we value transparency and a commitment to our mission to end ALS. We stand ready to be accountable for our commitments, when we excel and when we fall short. Here are the commitments we made in 2021 and where we stand one year later.
I AM ALS Names Laura Dalle Pazze its New Chief Executive Officer
I AM ALS named Laura Dalle Pazze its Chief Executive Officer. In her role, she leads a community revolutionizing a way to find treatments and cures for this fatal disease and helms the strategy for the next chapter of the organization’s future from start-up to sustaining movement.